11739 Results

People

  1. Vickers
    Vickers
  2. Offit
    Offit
  3. Robson
    Robson
  4. Horwitz
    Horwitz
  5. Kingham
    Kingham
  6. Panageas
    Panageas
  7. Breitbart
    Breitbart
  8. Halpern
    Halpern
  9. Jarnagin
    Jarnagin
  10. Nelson
    Nelson

Groups

  1. Population Sciences Research Program (11739)
  2. Survivorship Research (5670)
  3. Department of Medicine (5134)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3333)
  6. Surgery (2965)
  7. Psychiatry and Behavioral Sciences, Department of (2779)
  8. Biostatistics Service (2339)
  9. GSK Faculty (2008)
  10. Health Outcomes Research Group (1948)
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (7143)
  2. Meeting Abstract (3306)
  3. Book Section (330)
  4. Review (289)
  5. Editorial (253)
  6. Research Letter (116)
  7. Correspondence (111)
  8. Conference Paper (67)
  9. Guidelines (59)
  10. Miscellaneous (41)
  11. Book Whole (24)
Groups
  1. Population Sciences Research Program (11739)
  2. Survivorship Research (5670)
  3. Department of Medicine (5134)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3333)
  6. Surgery (2965)

More Groups

People
  1. Andrew Vickers (880)
  2. Kenneth Offit (788)
  3. Mark Robson (676)
  4. Steven Horwitz (645)
  5. T Peter Kingham (609)
  6. Katherine Panageas (512)

More People

Years
  1. 2025 (234)
  2. 2024 (722)
  3. 2023 (821)
  4. 2022 (828)
  5. 2021 (786)
  6. 2020 (738)

More Years

Publications
  1. Journal of Clinical Oncology (1246)
  2. Blood (374)
  3. Psycho-Oncology (347)
  4. Cancer (240)
  5. Cancer Research (234)
  6. Annals of Surgical Oncology (233)

More Publications

Publishers
  1. American Society of Clinical Oncology (1412)
  2. Elsevier Inc. (1128)
  3. Springer (1112)
  4. Elsevier Science, Inc. (816)
  5. Oxford University Press (753)
  6. Wiley Blackwell (614)

More Publishers

Results (11739)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II‐IV peripheral T‐cell lymphoma: Phase II results
    Meeting Abstract

    Lunning, M.; Horwitz, S.; Advani, R.; Vose, J.; Lee, H.; Mehta‐Shah, N.; Zain, J.; Haverkos, B.; Lechowicz, M.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Impact of pet imaging and histologic transformation on the prognosis of early disease progression in follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S. M.; Kumar, A.; Matasar, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT‐301, Cami) in relapsed/refractory (R/R) classical Hodgkin lymphoma (CHL)
    Meeting Abstract

    Collins, G.; Horwitz, S.; Hamadani, M.; Samaniego, F.; Spira, A.; Caimi, P.; Davies, A.; Menne, T.; Fields, P.; Cruz, H.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Risk of breast implant associated anaplastic large cell lymphoma (BIA‐ALCL) in a cohort of 3546 women prospectively followed after receiving textured breast implants
    Meeting Abstract

    Ghione, P.; Cordeiro, P. G.; Ni, A.; Hu, Q.; Ganesan, N.; Galasso, N.; Dogan, A.; Horwitz, S. M.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: Rationale for the phase 2 PRIMO trial
    Meeting Abstract

    Horwitz, S. M.; Foss, F. M.; Porcu, P.; Moskowitz, A.; Mehta‐Shah, N.; Jacobsen, E.; Khodadoust, M. S.; Kim, Y. H.; Weinstock, D.; Lustgarten, S.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Immunotherapy in colorectal cancer: Rationale, challenges and potential
    Review

    Ganesh, K.; Stadler, Z. K.; Cercek, A.; Mendelsohn, R. B.; Shia, J.; Segal, N. H.; Diaz, L. A. Jr
    Nature Reviews Gastroenterology & Hepatology (2019)

    Fulltext@MSK | Save
  • Towards controlled terminology for reporting germline cancer susceptibility variants: An ENIGMA report
    Guidelines

    Spurdle, A. B.; Greville-Heygate, S.; Antoniou, A. C.; Brown, M.; Burke, L.; de la Hoya, M.; Domchek, S.; Dörk, T.; Firth, H. V.; Monteiro, A. N.; more...
    Journal of Medical Genetics (2019)

    Fulltext@MSK | Save
  • Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: A scientific statement from the American Heart Association
    Guidelines

    Gilchrist, S. C.; Barac, A.; Ades, P. A.; Alfano, C. M.; Franklin, B. A.; Jones, L. W.; La Gerche, A.; Ligibel, J. A.; Lopez, G.; Madan, K.; more...
    Circulation (2019)

    Fulltext@MSK | Save